AstraZeneca enjoys rise in profits
Anglo-Swedish drugs giant AstraZeneca today reported an 8% rise in profits for the last quarter, helped by sales of its new ulcer treatment Nexium and asthma drug Symbicort, the group said today.
Pre-tax profits for the three months to June 30 rose to €1.1bn, while sales improved 8% to €4.4bn.